| Identification | Back Directory | [Name]
methyl (2S)-2-[[[(2R,3S,5R)-5-[5-[(E)-2-bromoethenyl]-2,4-dioxo-pyrimidin-1-yl]-3-hydroxy-oxolan-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate | [CAS]
232925-18-7 | [Synonyms]
NB1011
NB-1011
NB 1011
Thymectacin
L-Alanine, N-[5-[(1E)-2-bromoethenyl]-2'-deoxy-P-phenyl-5'-uridylyl]-, methyl ester
N-[[5-[(E)-2-Bromovinyl]-2'-deoxyuridin-5'-O-yl](phenoxy)phosphoryl]-L-alanine methyl ester
methyl (2S)-2-[[[(2R,3S,5R)-5-[5-[(E)-2-bromoethenyl]-2,4-dioxo-pyrimidin-1-yl]-3-hydroxy-oxolan-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate | [Molecular Formula]
C21H25BrN3O9P | [MDL Number]
MFCD06407664 | [MOL File]
232925-18-7.mol | [Molecular Weight]
574.32 |
| Hazard Information | Back Directory | [Uses]
Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (TS). Thymectacin is an aryloxy phosphoramidate derivative of BVdU (brivudin)[1][2]. | [References]
[1] Wilson RH. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist. 2006;11(9):1018-1024. DOI:10.1634/theoncologist.11-9-1018
[2] Congiatu C, et al. Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center. J Med Chem. 2006;49(2):452-455. DOI:10.1021/jm0509896 |
|
| Company Name: |
Pharma Affiliates
|
| Tel: |
172-5066494 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList694812/0_EN.htm |
|